Abstracts of the Breast Cancer Immunotherapy Symposium (BRECIS): Sidra Symposia Series
Foxp3 expression in breast cancer patient from Qatar: survival analysis
Journal for ImmunoTherapy of Cancer volume 3, Article number: O2 (2015)
In breast cancer, the presence of Foxp3 (Tregs)  within the tumor milieu has been a matter of debate. Some studies have determined that infiltration of Tregs was associated with poor survival, while others revealed no impact on survival, however this depends on their type, type of cells expressing Foxp3 and the density of the Tregs population .
The goal of our study was to quantify Foxp3 in breast cancer patients from Qatar and correlate with their survival.
Expression of FoxP3 was studied in 132 FFPE samples with known clinico-pathological data by immunohistochemistry technique and quantified by modified H-score system by pathologist. Results were analyzed via SPSS.
Analysis was carried for 132 patients. Age at time of diagnosis was 49 ±10.4 years. 76.2% of the patients showed positive expression of FoxP3. FoxP3 expression was not correlated with patient age or hormone receptors. Expression of Foxp3 positively correlate with better patient survival when compared to negative expression (94.1, 95% CI 85.6 - 102.6 versus 83.6, 95% CI 71.8 - 95.5, p 0.60).
FoxP3 is expressed on lymphocytes that are present in the tumor microenvironment regardless of breast cancer subtypes. Foxp3 is correlated with better survival.
Mackay C.R.: Dual personality of memory T cells. Nature. 1999, 401 (6754): 659-660. 10.1038/44309.
Mahmoud S.M., Paish E.C., Powe D.G., Macmillan R.D., Lee A.H., Ellis I.O., Green A.R.: An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Research and Treatment. 2011b, 127 (1): 99-108. 10.1007/s10549-010-0987-8.
About this article
Cite this article
Mohamed, M.G., Sarwath, H., Alqahtani, S. et al. Foxp3 expression in breast cancer patient from Qatar: survival analysis. j. immunotherapy cancer 3 (Suppl 1), O2 (2015). https://doi.org/10.1186/2051-1426-3-S1-O2
- Breast Cancer
- Breast Cancer Patient
- Survival Analysis
- Hormone Receptor
- Tumor Microenvironment